Statement: 80% of patients in the primary trial did not suffer any adverse events.
Primary_evidence: Adverse Events 1:   Total: 1/4 (25.00%)   Vertigo 0/4 (0.00%)   Abdominal adhesions 0/4 (0.00%)   Abdominal distension 0/4 (0.00%)   Abdominal pain 0/4 (0.00%)   Diarrhoea 0/4 (0.00%)   Nausea 0/4 (0.00%)   Vomiting 0/4 (0.00%)   Disease progression 0/4 (0.00%)   Influenza 0/4 (0.00%)   Nasopharyngitis 0/4 (0.00%)   Lumbar vertebral fracture 0/4 (0.00%)   Hyponatraemia 0/4 (0.00%)   Ataxia 0/4 (0.00%)